Therefore, the purpose of our study was to evaluate CT, MRI, and FDG PET/CT findings of sinonasal sarcoma, and to identify the features that differentiate sarcoma from SCC.
MATERIALS AND METHODS

Study Population
The Institutional Review Board approved the protocol for this study, and the requirement for obtaining informed consent was waived because routine diagnostic data were analyzed retrospectively.
By performing a medical record search in a single institution, we identified 7 patients (all men; mean age, 37.6 ± 13.9 years; age range, 18-58 years) with surgically confirmed sinonasal sarcoma who underwent CT, MRI, and FDG PET/CT between January 2003 and August 2014. For the purpose of comparison, we identified 13 patients (12 men, 1 woman; mean age, 61.8 ± 9.9 years; age range, 46-79 years) with surgically confirmed sinonasal SCC who also underwent CT, MRI, and FDG PET/CT during the same period. All imaging studies were performed in individual patients within 4 weeks.
The classification of the tumor stage was based on the American Joint Cancer Committee/Union Internationale Contre le Cancer staging 7th edition (7) .
Imaging Techniques
There was a slight variation in the imaging technique because several patients were referred to our tertiary cancer center from other hospitals after imaging was already performed using a variety of equipment and different protocols. Four CT, 3 MRI, and 2 PET/CT images from referring hospitals were accepted, provided that they were obtained within the appropriate time interval and were judged to be of sufficient quality by a head and neck radiologist or a nuclear medicine physician. At our institution, the imaging protocol for a head and neck mass is as follows.
CT
CT scans were conducted with a 16-MDCT scanner (MX8000 IDT; Philips Medical Systems, Best, the Netherlands) (n = 9) or a 256-MDCT scanner (Brilliance iCT; Philips Medical Systems, Cleveland, OH, USA) (n = 7). The technical parameters were as follows: pitch, 0.61-1.5; gantry rotation time, 50-270 ms; collimation, 4 × 1.5-6.4 × 0.625 mm; 120 kV; 132-200 mAs; and matrix, 512 × 512. Image acquisition was started 60 seconds after intravenous injection of 100-mL of non-ionic contrast materials (Omnipaque 300; GE Healthcare, Princeton, NJ, USA). The longitudinal field of view was typically from the level of the maxillary sinus to the tracheal bifurcation (mean coverage, 250 mm).
Axial, coronal, and sagittal images were reconstructed.
MRI
MRI scans were conducted with a 1.5-T MRI system (Gyroscan Intera; Philips Medical Systems, Best, the Netherlands) (n = 12) or a 3-T MRI system (Intera Achieva; Philips Medical Systems, Best, the Netherlands) (n = 5) using a head and neck coil. 
RESULTS
Clinical findings (age, sex, and pathologic tumor-node-metastasis stage) in patients with sarcoma and SCC are summarized in Table 1 .
The mean age of patients in the sarcoma group (37.6 ± 13.9 years) was significantly lower than that of patients with SCCs (61.8 ± 9.9 years) (p < 0.0005). No significant difference in the female-to-male ratio was observed between the two groups. Among seven sinonasal sarcomas, five tumors were located in the maxillary sinus. Histopathological diagnoses were undifferentiated pleomorphic sarcoma (n = 3), chondrosarcoma (n = 2), rhabdomyosarcoma (n = 1), and chondroid osteosarcoma (n = 1).
The CT, MR, and PET/CT imaging features of cases of sarcoma and SCC included in this study are summarized in Table 2 .
The most common CT and MRI features of sarcomas were an irregular shape (4/7, 57.1%), > 5 cm in the maximum dimension (4/7, 57.1%), a well-defined margin (6/7, 85.7%), iso-signal intensity on T1-weighted MRI (6/7, 85.7%), high signal intensity on T2-weighted MRI (7/7, 100%), homogeneous enhancement (4/7, 57.1%), and local tumor invasion (7/7, 100%). There were 
DISCUSSION
Sinonasal sarcomas are frequently misdiagnosed as carcinomas because the clinical symptoms are not quite different. Malignant head and neck tumors may have various imaging features according to their different histopathologic types (9) . Therefore, it is useful to assess the imaging features of this rare tumor that can help distinguish it from other common malignant tumors in the sinonasal region. SCC is the most common histological type of malignancy in the sinonasal region, accounting for 60% to 75% of all cases (10, 11) . Therefore, this study aimed at identifying the imaging features of sinonasal sarcoma using CT, MRI, and PET/CT based on our single-center experience.
The demographics of our patients with sinonasal sarcoma and SCC, including age and sex, were similar to those reported in previous studies (4, 12) . A large cohort study (12) reported that sinonasal SCC was twice as common in men than in women, and approximately 80% of the tumors occur in patients over the age of 55 years. In our series, the mean age of patients with sarco-mas was significantly less than that of patients with SCCs. When the age of 50 years was used as the cut-off value, the sensitivity and specificity for differentiating sarcoma from SCC were 71.4% and 84.6%, respectively. No significant difference in gender of patients was observed between the two groups because of extreme male predominance in both sarcoma and SCC. (15) . Sinonasal malignant fibrous histiocytomas revealed iso-or mixed density on CT, isoor mixed intensity on T1-weighted MRI, mixed intensity on T2weighted MRI, and heterogeneous enhancement (16) . Various types of contrast enhancement may be explained by the different histological subtypes and different grades of tumors. In our study, sarcoma and SCC showed nearly identical MRI features with isosignal intensity on T1-weighted images and high signal intensity on T2-weighted images. Therefore, there was a significant overlap in the CT and MRI appearances of sarcomas and SCCs in our series.
In general, sarcomas tend to be FDG avid, although there is significant variability. Previous studies (17) (18) (19) (20) have reported that there is a relationship between the SUV level and the histological grade of soft tissue sarcomas. High-grade sarcomas tend to accumulate FDG at a higher rate than low-grade tumors because of the greater energy needs of tumors and upregulation of glucose transporters.
In our study, all 7 patients showed FDG uptake in the sinonasal sarcoma group with a SUVmax of 5.1 or greater. Our mean SUVmax value of 7.4 was lower than the values reported in the literature (17, 18) . On comparison between sarcomas and SCCs, the SUVmax value was the only parameter that was significantly different be-tween the two malignant tumors. With the use of a cut-off value, a SUVmax value < 10.0 had a sensitivity and specificity of 85.7% and 76.9%, respectively, for sinonasal sarcoma.
This study has several limitations. First, an important limitation was the small sample size, given the rarity of this tumor. We could not evaluate the correlation between imaging findings obtained using three different diagnostic modalities due to low statistical power. Furthermore, because our sample consisted of various histological subtypes of sarcomas, the results cannot be generally applied to sinonasal sarcoma. Second, all patients included in this study were recruited from a head and neck cancer center at a single tertiary hospital. All sarcomas and SCCs in our series showed local tumor invasion at the time of diagnosis.
These findings suggest that our patients seemed to have more aggressive tumors compared to those that have been reported by other researchers.
In conclusion, CT and MRI parameters were not useful in differentiating between sinonasal sarcomas and SCCs. Only the SUVmax value < 10.0 was a significant imaging feature of sarcoma for differentiation from SCC.
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